For your IC patients

URO IC CONGRESS
Launches
First oral medication approved to treat pain & discomfort in IC

A Global Interstitial Cystitis Initiative by

Inlicensed from Wave Bionomics, Switzerland

URO IC CONGRESS

Website: www.iccongress.eu E-mail: info@iccongress.eu Tel: +91 22 6150 5222

Leading Force Behind IC Congress . . .

Vishal Jajodia, the CEO, is the Chief Innovator and Visionary of Swati Spentose Pvt. Ltd. (Euresian Group). The Group, establish in 1970, is now present in more than 54 countries world wide. He is also active in several platforms under the Ministry of Commerce. Vishal Jajodia is gallant in launching three new molecules for the world market, out of which one of them is a New Chemical Entity (NCE), which is to be launched for the first time on an international platform, in collaboration with globally notable scientists from Australia, Europe & USA. He is a leader from the new world of social entrepreneurship, where he has taken the lead to make the change, in the way Interstitial Cystitis is managed and looked at, which has resulted in the multidimensional and multifaceted scientific capabilities, on manufacturing and clinical applications of Pentosan. In his own words:

Supported by A World Class Platform . . .

A USD 10 million world class dedicated manufacturing facility for pentosan, complying global FDA regulations worldwide. Largest commercial manufacturer of Pentosan in the world. Fully backward integrated for the key starting raw material, to be the cheapest and most cost competitive in the world. SSPLs Pentosan has been approved by the originator, IVAX. Forward integrated with new applications for the same molecule at prestigious Mount Sinai School of Medicine, New York. Comparative preclinical studies of SSPLs Pentosan with the originator molecule at the Mount Sinai School of Medicine, New York which have confirmed that they have similar activities. Top world scientists on the molecule pentosan in scientific collaboration with us for the chemistry of the molecule. Top world class clinicians with 20 years of experience on treating IC under IVAX, the originator are our advisory board. Launching our own brands globally in collaboration with Wave Bionomics, GmbH, Switzerland. Taking the IC initiative global in collaboration with URO IC Congress, Switzerland.

Vishal Jajodia, CEO

Swati Spentose Pvt. Ltd.

''We want to put life in healthcare, we empathize with the people who have been suffering without medication. We are social entrepreneurs and are medicating responsibly towards this cause of IC patients

Complementing healthcare solutions in IC: New NSAID for chronic pain management. Dimethyl Sulfoxide (DMSO) for intravesical delivery. Collaboration with the Father of DMSO. Global leaders on lidocaine.

URO IC CONGRESS

Team of Scientists
Dr. Gary Striker
Dr. Gary Striker is a Professor of Medicine, Division of Nephrology, Mount Sinai School of Medicine, NY. He has over 45 years of scientific research experience with 200+ publications across disease areas and holds patents on the use of PPS for use in vascular/kidney disease, prostate disease, etc. He is now associated with SSPL for research activities on PPS for diseases such as Diabetic Nephropathy, Gangrene, Cardio Vascular Disease, Trauma, etc.

Team of Clinicians...
Dr. David Kaufman, M.D.
Diplomate of the American Board of Urology. Dr. Kaufman has been certified by the American Board of Urology since 1991, and is a member of the American Urological Association.

LEAD TEAM OF SCIENTISTS

URO IC CONGRESS

THE TORCH BEARERS

Dr. Kristene Whitmore, M.D.

Medical director of the Pelvic and Sexual Health Institute in Philadelphia, PA. She is chair of urology and female pelvic medicine and reconstructive surgery as well as professor of urology and OBGYN at Drexel University College of Medicine.

Dr. Helen Vlassara

Dr. Vlassara has been involved in preclinical studies in animal models for studying the use of PPS in AGE related disorders and complications. She has conducted extensive, innovative research in areas as diverse as atherosclerosis, kidney disease, and disorders of the central nervous system.

Dr. Joel Teichman,MD, FRCSC

Dr. Teichman is Associate Professor of Surgery/ Urology at the University British Columbia and Head of the Division of Urology for Providence Healthcare, Vancouver, BC, Canada.

Dr. Yogeshwar Kalia

Dr. Yogeshwar Kalia is a senior lecturer at the University of Geneva, Switzerland. He has published ~80 papers, presented ~75 abstracts at international conferences and is a coinventor on 4 patents. He is working with SSPL to develop NDDS for PPS using his research in collaboration with the University of Geneva.

Dr. J. Curtis Nickel MD, FRCSC

Dr. J. Curtis Nickel completed his undergraduate, surgical, urological and research training in Canada. He has been a member of the Department of Urology at Queens University since 1984 and was promoted to full Professor in 1994.

Dr. Stanley Jacob

Dr. Stanley Jacob is widely known as the Father of DMSO. He is M.D. cum laude from Ohio State University and performed residence and surgical fellowship at Harvard Medical School. He holds 3 patents including the initial patent on the therapeutic implications of DMSO. SSPL has collaborated with him to launch DMSO in new applications across various new segments, and new delivery methods.

Dr. Nagendra Mishra

Dr. Nagendra Mishra is consultant urologist in Kidney and Urology hospital in Ahmedabad. His main interest is Interstitial Cystitis / Painful Bladder Syndrome (IC/PBS) .He is founder chairman of Indian IC/PBS society.

Mr. Hans Jahns

Mr. Hans Jahns is our scientific associate for development of new salts of known NSAID for chronic pain management with minimal side effect.

Dr. Rajeev Sood

Dr Rajeev Sood is Urology faculty and Head of the Department at Dr Ram Manohar Lohia Hospital & PGI MER, New Delhi. He is part of the IC/PBS Society releasing Guidelines for IC/PBS in 2009. Currently holding the position of Hon. Secretary, NZC-Urological Society of India.

URO IC CONGRESS

URO IC Congress objectives...

Objective: To build a Global URO IC Congress under the aegis of Swati Spentose Pvt. Ltd, a subsidiary of the Euresian Group, Mumbai, India (SSPL/EG). The focus of IC Congress will be to build awareness and disseminate information on Interstitial Cystitis in India and then take the platform globally with the assistance of international Key Opinion Leaders and Medical Experts in Interstitial Cystitis diagnosis, treatment and research.

Our other UROLOGICAL PRODUCT Basket to cater to your prescription needs

DUTRIDE T
A brand of tamsulosin plus dutasteride

DUTRIDE
A brand of Dutasteride

Goals of the URO IC Congress: 1. To form a gold standard organization consisting of high caliber professionals specialized in the subject of IC diagnosis, treatment, and research. 2. To determine incidence/prevalence of Interstitial Cystitis in different geographic and demographic regions of interest to better allocate resources for education and training. 3. To identify the target population in each geographic region. 4. To determine the best teaching tools suited to the target population in each geographic region. 5. To expand the fund of existing knowledge in Interstitial Cystitis through contributions in research, continuing medical education, and education for patients and the general public. 6. To assist in the establishment of a physician network of Key Opinion Leaders in geographic areas of interest. 7. To help develop a rich data base of patient demographics for Interstitial Cystitis in geographic areas of interest. 8. To assess the current level of physician knowledge and experience in caring for patients with IC in each geographic region through online research, communication with local physicians and when necessary, site visits. 9. To help organize patient support groups for IC in geographic regions of interest.

TEROD
A brand of tolterodine

Finflow
A brand of finasteride

TAMYSIN
A brand of tamsulosin

URO IC CONGRESS